Voloridge Investment Management
ELVN icon

Voloridge Investment Management’s Enliven Therapeutics ELVN Stock Holding History

Voloridge Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,656
Closed -$354K – 1230
2025
Q2 		$354K Buy
+17,656
New +$334K ﹤0.01% 1101
2024
Q4 		– Sell
-17,320
Closed -$442K – 1233
2024
Q3 		$442K Buy
17,320
+5,665
+49% +$131K ﹤0.01% 1091
2024
Q2 		$272K Buy
+11,655
New +$245K ﹤0.01% 1155

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Voloridge Investment Management's ELVN Position: Q3 2025 in Review

Voloridge Investment Management sold out of Enliven Therapeutics (ELVN) in Q3 2025, closing a stake of 17,656 shares — an estimated $354K sold.

Voloridge Investment Management first reported a position in ELVN in Q2 2024 and held it in 3 quarters. The position peaked at $442K in Q3 2024. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • Voloridge Investment Management reported no remaining Enliven Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 17,656 Enliven Therapeutics shares in Q3 2025, an estimated $354K.
  • Voloridge Investment Management first reported a position in Enliven Therapeutics in Q2 2024 and held it in 3 quarters.
  • Voloridge Investment Management's Enliven Therapeutics position peaked at $442K in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on Voloridge Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.